Xoma's Gevokizumab Fails Phase III Trial Thursday, July 23, 2015 Xoma have announced that their monoclonal antibody gevokizumab it is co-developing with Servier has failed the Phase III EYEGUARD-B trial in patients with Behçet's disease uveitis.Researchers Develop Vaccine that Protects Primates Against Ebola Thursday, July 23, 2015 A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola. Universal Flu Vaccine in the Works Wednesday, July 22, 2015 A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection. Immunotherapy Shows Promise for Myeloma Wednesday, July 22, 2015 A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable. PacBio, Singapore's GIS Expand Collaboration on Infectious Disease Wednesday, July 22, 2015 Together, GIS and PacBio will combine efforts to advance research in infectious diseases, genomics, sequence analysis, and translational healthcare in Singapore. Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease Tuesday, July 21, 2015 Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).Ingenza Embarks on GSK Collaboration Tuesday, July 21, 2015 Ingenza Ltd, a world leader in the application of industrial biotechnology and synthetic biology, is pleased to announce that it is collaborating with global healthcare company GlaxoSmithKline (GSK) on an innovative research project.
GSK, Francis Crick Institute Collaborate Monday, July 20, 2015 This partnership sets out to explore new avenues of medical research and drug discovery across a broad range of diseases, with a view to achieving breakthroughs in the understanding of human disease.Epirus, Polpharma Collaborate Monday, July 20, 2015 This deal will see the companies partner on the clinical development and regulatory filings for a number of Epirus Biopharmaceuticals biosimilar products.